Premium
Designer drug 2,4,5‐trimethoxyamphetamine (TMA‐2): Studies on its metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques
Author(s) -
Ewald Andreas H.,
Fritschi Giselher,
Maurer Hans H.
Publication year - 2006
Publication title -
journal of mass spectrometry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 121
eISSN - 1096-9888
pISSN - 1076-5174
DOI - 10.1002/jms.1059
Subject(s) - chemistry , urine , chromatography , oxidative deamination , gas chromatography–mass spectrometry , deamination , demethylation , designer drug , metabolism , hydrolysis , metabolite , extraction (chemistry) , mass spectrometry , drug , organic chemistry , biochemistry , enzyme , pharmacology , medicine , gene expression , dna methylation , gene
Studies are described on the metabolism and the toxicological detection of the amphetamine‐derived designer drug 2,4,5‐trimethoxyamphetamine (TMA‐2) in rat urine using gas chromatographic/mass spectrometric (GC/MS) techniques. The identified metabolites indicated that TMA‐2 was metabolized by oxidative deamination to the corresponding ketone followed by reduction to the corresponding alcohol, O ‐demethylation followed by oxidative deamination, and finally O , O ‐bis‐demethylation. All metabolites carrying hydroxy groups were found to be partly excreted in urine as glucuronides and/or sulfates. The authors' systematic toxicological analysis (STA) procedure using full‐scan GC/MS after acid hydrolysis, liquid‐liquid extraction, and microwave‐assisted acetylation allowed the detection, in rat urine, of an intake of TMA‐2 that corresponds to a common drug users' dose. Assuming similar metabolism, the described STA procedure in human urine should be suitable as proof of an intake of TMA‐2. Copyright © 2006 John Wiley & Sons, Ltd.